Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;39(1):243-247.
doi: 10.1038/s41375-024-02441-1. Epub 2024 Oct 21.

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Keito Suto  1 , Norio Takei  2 , Keito Yokoyama  1 , Masahiro Chiba  1 , Takashi Ishio  1 , Michiyuki Maeda  3 , Hideki Goto  1 , Tomoyuki Endo  1 , Takanori Teshima  1 , Yibin Yang  4 , Masao Nakagawa  5
Affiliations

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Keito Suto et al. Leukemia. 2025 Jan.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: MN received research funding from Takeda Pharmaceutical Company Limited. The other authors declare no competing financial interests related to this work.

References

    1. Horwitz S, O’Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288–98. - DOI - PubMed
    1. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095–100. - DOI - PubMed - PMC
    1. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6. - DOI - PubMed
    1. Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376–84. - DOI - PubMed - PMC
    1. Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood. 2022;140:1951–63. - DOI - PubMed - PMC

LinkOut - more resources